All News

RheumNow Podcast square

RheumNow Podcast - EULAR 2021 & EULAR-IQ (6.4.21)

d Jack Cush, MD

Dr Jack Cush reviews highlight presentations from the first 3 days of EULAR 2021.


Read Article
computer.health.jpg (keep)

EULAR Best Abstracts - Day 2

d Jack Cush, MD

The second day of EULAR 2021 took a big leap in online content.  #EULAR2021 generated 2500 tweets yesterday. Here is a compilation (with links) of presentations were the “Best” as seen by our RheumNow faculty. 

Read Article
grappa sign treatment recommendations

New GRAPPA 2021 PsO and PsA Treatment Recommendations

d Rachel Tate, DO

The evidence-based recommendations from the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis were presented at #EULAR2021.

Read Article
Lupus.right_.jpg

Is Rituximab and Belimumab the Combination to Beat Lupus?

d Eric Dein, MD

On day 2 of EULAR conference, Dr. Michael Ehrenstein presented OP0129, a presentation on the BEAT-LUPUS trial looking at belimumab therapy after rituximab. B cell depletion with rituximab is common treatment for refractory SLE, though real-world data for rituximab has been uncertain. It is known that B-cell activating factor (BAFF) levels can increase after rituximab, which can lead to disease flares. Using belimumab, a human monoclonal antibody inhibiting BAFF, could be a potential therapeutic option after rituximab infusions. 

Read Article
A biosimilar to placebo! #POS0276 study eval krill oil for knee pain. 452 participants randomized to krill oil 2 g/d X 24 wks. no difference in knee pain function, lipids, inflammation, leg strength or adverse events #EULAR2021 @rheumnow https://t.co/cajz6sfhzn
k dao KDAO2011 ( View Tweet)
Exercise won't flare your disease #POS0404 Study of DBA/1 RA prone mice compared: exercised vs. not mice that exercised: - did NOT have⬆️in IL6, TNFa, IL17A - had⬇️levels of sclerostin - did NOT get enthesial mineralizat'n #EULAR2021 @rheumnow https://t.co/REP2UKp7Ci
k dao KDAO2011 ( View Tweet)

JAKi has better retention than a bDMARD in RA! Single site study of RA pts prescribed advanced therapy in 320 Rxs in 215 pts JAKi lasted longer adjusting for age, sex, RA duration & line of therpy & 1st line Rx POS0205 #EULAR2021 @RheumNow https://t.co/4m2RXBkTDr

Janet Pope Janetbirdope ( View Tweet)
Dr Mulhearn presents that excess GCA cases are associated with COVID-19 peaks. Annual incidence rate of 13.7/100,000 in 2019 and 29.8/100,000 in 2020. Interesting, needs replication! @RheumNow #EULAR2021 Abstr#OP0281 https://t.co/kDk7ARnxMn
Richard Conway RichardPAConway ( View Tweet)
Enthesitis response to SEC over 24w in PsA pts from ULTIMATE? ➡️ULTIMATE: 52w DB, PIII RCT that showed sign impr of synovitis (PDUS-detected) w/ SEC vs PBO in pts w/ PsA ➡️OP0226: SEC improved enthesitis at wk 12 & 24 per SPARCC & Global OMERACT-US scores #EULAR2021 @RheumNow https://t.co/QiCo4CVHz3
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
Can we identify #SLE patients who cd benefit from earlier bDMARDs? Dr Hassan showed 105/209(50%) pts required bDMARDs/Cyclophosphamide. Time-to-therapy was associated with⬇️C3/C4 and⬆️cSLEDAI-2K. More works needed re: biomarkers & varied population #EULAR2021 #POS0175 @RheumNow https://t.co/gK7Ew3WJUj
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Sentinel joint! #POS0385 Study of 524 preclinical RA followed 2 yrs found that intermetatarsal bursitis (IMB) can predict devl't of RA esp in ACPA+ pts 👉>70% w/abnormal IMB dev RA over 1 yr 👉synovial lining is found in the intermetatarsals #EULAR2021 @rheumnow https://t.co/RQzZRh1eC2
k dao KDAO2011 ( View Tweet)

Do you think that JAK1 selectivity matters in rheumatological clinical practice? #EULAR2021 @RheumNow

David Liew drdavidliew ( View Tweet)

Does vit D level predict response to RA Rx? Yes...maybe! POS0100 showed in 236 RA pts, 57% starting TNFi, rest other bDMARDs, at 1 yr, good responders & remission 4x less likely to respond if low vit D but sig for DAS(ESR) not CDAI/SDAI. ?Give VIT D to all! #EULAR2021 @RheumNow

Janet Pope Janetbirdope ( View Tweet)

"PsA is the most common co-morbidity in pediatric PsO patients (OR - 5.3), the second is obesity." Dr. Yonathan Butbul. It is estimated that 1/3 of PsO pts will have juvenile disease onset, but may not be diagnosed until adulthood. #EULAR2021 @RheumNow

Dr. Rachel Tate uptoTate ( View Tweet)

Guselkumab in patients with active #Psoriatic_Arthritis & who failed anti-TNF: COSMOS study Phase 3b A new option for the difficult-to-treat patients with PsA @DrLauraCoates #EULAR2021 https://t.co/2aOqZYfbsT
Nelly ZIADE 🍀 Nellziade ( View Tweet)
Upacitinib in #Psoriatic_Arthritis with axial manifestations Post hoc analysis from SELECT PsA1/2 #EULAR2021 @deodhara https://t.co/867c2J3DiI
Nelly ZIADE 🍀 Nellziade ( View Tweet)
Very interesting 🤔 talk about the role of #comorbidities in difficult to treat #RA by our fabulous #emeunet past chair @ElenaNikiUK at #EULAR2021 @eular_org https://t.co/zyQ0DkKhbu
EMEUNET EMEUNET ( View Tweet)
NEW RESEARCH—Safety and efficacy of #rituximab in #SystemicSclerosis (DESIRES): a double-blind, investigator-initiated, randomised, placebo-controlled trial https://t.co/Sb3d1kPhL4 #LancetRheumatology https://t.co/4SMVGY0C3M

Links:

The Lancet Rheumatology TheLancetRheum ( View Tweet)
Potential new player on the block, B-cell associated cytokine IL-40 in #Sjogren. Dr Rizzo showed ⬆️IL40 expression in salivary gland biopsy & bloods in pSS and pSS-associated lymphoma. Future work will clarify the exact role of IL-40 as a tx target #EULAR2021 #POS0177 @RheumNow https://t.co/uXAYAlkdtD
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)

⭐️Deucravacitnib = oral TYK2i w/ downstream inhibitory effects on IL23, IL12 & type I IFN pathways ⭐️Recent studies (POETYK PSO-1/2) show that it outperforms Otezla per PASI75 ⭐️OP0227 shows it is also efficacious for active PsA vs PBO w/ no serious AEs #EULAR2021 @Rheumnow https://t.co/qA1NsLzQsF

Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
×